Shanghai Haohai Biological Technology Co., Ltd. logo

Shanghai Haohai Biological Technology Co., Ltd. (688366)

Market Open
11 Aug, 06:57
SSE SSE
¥
32. 52
-0.26
-0.7932%
¥
13.72B Market Cap
- P/E Ratio
1.6% Div Yield
269,801 Volume
- Eps
¥ 32.78
Previous Close
Add Transaction
Day Range
32.4 33.28
Year Range
27.6 58.97
Want to track 688366 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

688366 trading today lower at ¥32.52, a decrease of -0.7932% from yesterday's close, completing a monthly increase of 14.79% or ¥4.19. Over the past 12 months, 688366 stock lost -26.2919%.
688366 pays dividends to its shareholders, with the most recent payment made on Jun 17, 2026. The next estimated payment will be in In 4 months on Dec 17, 2026 for a total of ¥0.6.
The last earnings report, released on Apr 24, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Shanghai Haohai Biological Technology Co., Ltd. has completed 1 stock splits, with the recent split occurring on Jun 20, 2024.
The company's stock is traded on one exchange.

688366 Chart

People also search for

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.
¥ 140.8
+0.7369%
Shanghai United Imaging Healthcare Co., Ltd.
¥ 112.74
+0.0355%
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
¥ 30.71
+0.8207%
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. A Shares
¥ 140
+2.1898%
Beijing Tiantan Biological Products Co., Ltd.
¥ 12.85
+0.5477%

Shanghai Haohai Biological Technology Co., Ltd. (688366) FAQ

What is the stock price today?

The current price is ¥32.52.

On which exchange is it traded?

Shanghai Haohai Biological Technology Co., Ltd. is listed on SSE.

What is its stock symbol?

The ticker symbol is 688366.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 1.6%.

What is its market cap?

As of today, the market cap is 13.72B.

Has Shanghai Haohai Biological Technology Co., Ltd. ever had a stock split?

Shanghai Haohai Biological Technology Co., Ltd. had 1 splits and the recent split was on Jun 20, 2024.

Shanghai Haohai Biological Technology Co., Ltd. Profile

Biotechnology Industry
Healthcare Sector
Dr. Yongtai Hou Ph.D. CEO
SSE Exchange
CNE100003NX4 ISIN
DE Country
2,156 Employees
17 Jun 2026 Last Dividend
20 Jun 2024 Last Split
- IPO Date

Overview

Shanghai Haohai Biological Technology Co., Ltd., established in 2007 and headquartered in Shanghai, China, stands as a paramount figure in the biomedical materials industry, not only within its domestic borders but also internationally. The company initially known as Haohai Limited until its rebranding in 2010, has carved a niche for itself through its dedication to research, development, manufacture, and sale of a wide range of biomedical products. Engaging in a broad spectrum of sectors, including ophthalmology, medical aesthetics, biological engineering, and pharmaceutical products, Shanghai Haohai Biological Technology Co., Ltd. also extends its expertise to technology transfer and consultation services. This multifaceted approach underscores the company’s commitment to advancing healthcare through innovation.

Products and Services

Shanghai Haohai Biological Technology Co., Ltd.'s portfolio encompasses an extensive array of products and services designed to meet the diverse needs of the medical and healthcare communities:

  • Ophthalmology Products: This range includes intraocular lenses for cataract surgery, medical sodium hyaluronate gel for ophthalmic surgery assistance, and lubricant eye drops for dry eye relief.
  • Sodium Hyaluronate Injection: Primarily used in joint disorders, these injections serve as a lubricant and shock absorber, providing pain relief and improved mobility.
  • Medical Chitosan: This biopolymer has diverse applications, including wound healing and as a biomaterial in tissue engineering.
  • Anti-Adhesion and Burn Wound Products: These products are designed to prevent post-surgical adhesions and aid in the healing of burn wounds, enhancing recovery outcomes.
  • Medical Aesthetics Products: The company’s foray into medical aesthetics includes Matrifill, a first-generation HA dermal filler for skin volume restoration; Janlane, a second-generation HA dermal filler tailored for dynamic wrinkles; and Hyalumatrix, a third-generation HA dermal filler that specializes in precise facial contouring. Additionally, the company offers genetic-engineering preparations for epidermal repair and devices for aesthetic procedures, such as radio frequency and laser equipment.
  • Biological Engineering and Pharmaceutical Products: Engaging in cutting-edge research and development, Shanghai Haohai provides innovative solutions that span biological reagents, biologicals and biological materials. This segment also involves the manufacture and sale of related machinery and accessories.
  • Technology Transfer and Consultation Services: Beyond product development and manufacturing, Shanghai Haohai plays a pivotal role in the dissemination of knowledge and technology, facilitating advancements in medical practices through effective consultation and technology transfer services.

Contact Information

Address: WenGuang Plaza, Shanghai, China
Phone: 86 21 5229 3555